The Latest in the Legal Battle for Psilocybin Access for Patients
This case marks another development in the years-long efforts to make psilocybin legally accessible for patients for therapeutic purposes.
On Friday, October 20th, the Ninth Circuit Court of Appeals heard Aggarwal v. United States Drug Enforcement Administration, which centered around the efforts of Sunil Aggarwal, MD to be able to provide psilocybin for terminally ill patients and patients with anxiety and depression (1,2). Dr. Aggarwal, a palliative care physician, is a co-founder of the Advanced Integrative Medical Science Institute (AIMS), which is “an outpatient clinic and research institute dedicated to advancing integrative medical care, research, and education within oncology, psychiatry, neurology, rehabilitation, pain, and palliative care,” (2). For the past few years, he and his team have been taking legal actions to make psilocybin widely and legally accessible, including filing a petition to reschedule psilocybin, which was denied by the Drug Enforcement Administration (DEA) in September 2022 (1,2).
“The [current] case seeks federal court review of the DEA’s denial of a petition to reschedule psilocybin (commonly called magic mushrooms) from a highly restricted Schedule I drug to a less restricted Schedule II so that it can be accessed by physicians and other providers to help those with terminal and other life-threatening conditions,” stated a press release on the AIMS website (2). “This case focuses on DEA’s long history of applying an inaccurate test to rescheduling petitions. The outcome of this case could have implications for other emerging and promising therapies.”
Other statements presented by the lawyers representing Dr. Aggarwal included arguments that the DEA did not fully consider the evidence that they had presented in their petition supporting psilocybin as having current accepted medical use, and the argument that the petition should be referred to the Department of Health and Human Services (HHS) (1).
Watch the full case here (starting at 1 hour and 36 minutes into the clip).
For in-depth insight into Dr. Aggarwal’s accomplishments and goals, read The Path to Legalized, Accessible Psilocybin Therapy from our psychedelics issue,Psychedelics: New Frontiers in Alternative Medicine.
References
- Adlin, B. Federal Court hears case challenging DEA decision to deny psilocybin rescheduling petition without consulting health officials https://www.marijuanamoment.net/federal-court-hears-case-challenging-dea-decision-to-deny-psilocybin-rescheduling-petition-without-consulting-health-officials/ (accessed Oct 23, 2023).
- Media Advisory for federal appeals court - psilocybin case hearing https://www.aimsinstitute.net/media-advisory-for-federal-appeals-court-psilocybin-case-hearing/ (accessed Oct 23, 2023).
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.
Ep 24, Part II: Data Transparency in Cannabis Testing with Yasha Kahn
December 12th 2024Evan Friedmann and Yasha Kahn, co-founder of MCR Labs, discuss the discrepancies between current regulations and data on mycotoxins and pesticides in cannabis products. They highlight the need for updated regulations based on new data, emphasizing the importance of accurate testing and labeling. They also discuss the issue of result manipulation, particularly in THC content, and the need for public health officials to address this. Yasha suggests making testing data public to enhance oversight and suggests a national entity to manage this data for better consistency and public safety.
